Today’s AI Top Pick: ORCL

7/20/2026 · Turnaround Undervalued Accumilate screen · a free sample of K3vl4r’s AI-curated picks.

AI-ranked from a screened shortlist, with entry strategy, targets, and risks.

View the live ORCL price forecast →

Today's pick · Turnaround Undervalued AccumilateORCLBUY NOW9.1 / 107/20/2026

Oracle is the textbook 'turnaround/accumulate' setup in this pool: the fundamentals are elite for the price and the tape has already done the ugly work. On a fwd P/E of 11.59, PEG 0.44, ROE 54.28%, profit margin 25.21%, and operating margin 33.32%, you are buying a mega-cap software franchise (mkt cap $364B, sales YoY +17.35%) at a valuation that does not match the profitability. Analyst recom is 1.51 with targetUpsidePct of 101.6% — essentially the sell-side is calling it a double from here — yet the stock is down -49.18% over the past year and -35.14% YTD. That is exactly the mismatch this screen is hunting. The multi-timeframe forecast tape confirms rather than fights the fundamentals. 1h fc_long +25.54%, 4h fc_long +42.22%, 1d fc_short +11.84 / fc_mid +41.45 / fc_long +47.89%, and even the 1wk fc_long is still positive at +5.06%. Bullish_prob = 1.0, near_term_bullish = 0.8, and RSI 29.25 is deeply oversold. Critically, position_in_21bar_range_pct is 15.56 / 6.36 / 2.34 / 1.49 across 1h/4h/1d/1wk — you are NOT chasing; you are buying near the low of the recent range with a -31.61% daily drawdown from the 21-bar high. That is the entry the lens is designed to find. The headline that matters ('Oracle Crashed 65% From Its Peak. I Just Bought It Anyway') captures the setup — the 52-week-low print last week is the capitulation, and Oracle just announced an AI/Cloud studio partnership with IMSA Labs, giving a forward catalyst. There is no dilution, no fraud allegation, no guidance-cut headline in the recent news — just price damage. Contrast that with FUTU (DOJ probe + class actions), CELH (UK ban chatter + PT cuts), LX (credit fears), CWH (analyst PT trims) and MVST (governance investigation) — those all pass the screen on paper but have live landmines. ORCL does not. Why today, not later: you already have oversold RSI, position near 0% of the 21-bar range on daily/weekly, and forward forecasts of +40%+ on the daily. Waiting for a 'better' entry when you are already 44% below the 21-bar weekly high is trying to catch the exact bottom; the risk/reward is asymmetric right here, with a clean invalidation just under the recent low.

ORCL forecast chart
Entry zone
$124-$127 (scale in around current $125.71, add on any dip to $122)
Stop loss
$114 (below the recent capitulation low; ~9% risk)
First target
$150-$155 (mean reversion toward the 21-bar daily high, +19-23%)
Longer target
$180-$195 (aligning with 1d fc_mid/long +41-48% and analyst target upside)
Risks
  • Weekly trend still broken — dd_from_21bar_high_pct is -44.13% on 1wk, meaning overhead supply is heavy and rallies may be sold
  • Debt/Equity is 3.94 — highest in the pool; any cloud capex disappointment or rate re-acceleration hurts the multiple
  • 1wk fc_short is -3.55%, hinting the very-near-term weekly tape could still chop lower before the daily forecast plays out
  • Concentrated AI/cloud narrative — a single soft OCI booking print could re-trigger the selloff that took it to a 52-week low last week
  • Broader market context shows NFLX/ORCL/SPCX all hit 52-wk lows together — mega-cap risk-off tape isn't fully cleared
Honorable mentions
BILIFwd P/E 13.69, PEG 0.54, recom 1.3, and a fresh $300M buyback announced. Near_term_bullish 1.0 with 1d fc_mid +42% and 4h fc_long +25%. Only knock is 1h/4h position at 93-100% of range, so you're paying up slightly vs ORCL's deep discount.
NAGEFDA Rare Pediatric Disease designation for NB4168 is a real catalyst, ROE 27%, profit margin 14.3%, fwdPe 11.52, recom 1.0, targetUpsidePct 265.9%. 1d fc_mid +83%. Held back by 1wk fc negative and micro-cap ($261M) liquidity risk — best as a smaller-size pullback buy.
Full ranking (26)
#SymbolVerdictScoreRead
1ORCLBUY NOW9.1Deep-value mega-cap at RSI 29, 1-2% of 21-bar range, all TFs forecast up, +101% analyst upside, no bad news.
2BILIBUY NOW8.2PEG 0.54, recom 1.3, fresh $300M buyback, 1d fc_mid +42% with bullish_prob 1.0.
3NAGEBUY NOW7.6FDA rare-pediatric-disease designation catalyst + 27% ROE + fwdPe 11.5 + 1d fc_mid +83%.
4STEPBUY NOW7.2All four TFs forecast +positive (1d fc_mid +27.77%), near_term_bullish 1.0, sales YoY +69.89%.
5MLCOBUY NOW7.0Fwd P/E 7.92, PEG 0.35, 1wk fc_long +54.71%, 'worst is behind us' narrative confirming.
6YMMBUY NOW6.9Profit margin 32.68%, debt/eq 0, all TFs green on recent action, analyst upgrade to Buy this month.
7PGYBUY PULLBACK6.4Best-in-pool PEG 0.20 and recom 1.0, but 1wk fc turns negative -48.8% — needs a dip before adding.
8HLIBUY PULLBACK6.2Clean fundamentals and 1d fc_mid +20%, but 1wk forecasts negative and PT cuts from KBW/MS.
9ZBUY PULLBACK6.01wk fc_long +85%, but position_in_21bar_range 100% on 1h/4h/1d — you'd be chasing.
10ZGBUY PULLBACK5.9Same Zillow thesis as Z, marginally worse recom (1.97) and also pinned at range top.
11APOWAIT5.8Solid alt-asset franchise but 1wk forecasts all negative (-7 to -9%) and range near top.
12KKRWAIT5.6At 100% of range on 1h/4h/1d with fc_short negative; Oppenheimer just cut PT — bad entry timing.
13INTRBUY PULLBACK5.5Fwd P/E 5.42 and 1d fc_short +36.5%, but 1wk drawdown -35% signals broken weekly trend.
14PSIXBUY PULLBACK5.41d fc_mid +133%, ROE 75%, but 1wk fc long -31% is a big red flag on the higher TF.
15FLUTWAIT5.2Attractive daily forecast +65% but 1h forecasts negative and 1h position at 0% of range — no clean setup.
16MNDYWAIT4.91wk fc_long +160.75% is an outlier while 1h/4h are weak — probability-weighted this is too noisy.
17TPGWAIT4.7PE 200, low expected_return_pct (+1.2%), 1wk fc negative — no edge here.
18CELHAVOID4.5UK ban headlines + PT cuts undercut the +56% daily forecast; live regulatory landmine.
19FUTUAVOID4.2DOJ probe + class actions — do not front-run legal risk regardless of the 42% ROE.
20LXAVOID4.0Credit-fears headlines + -76% year and -3.4% sales — cheap for a reason, sales going wrong way.
21BURAVOID3.8Extreme forecasts but ROE -98%, sales YoY -335%, negative broader Iran-war headline drag.
22PARAVOID3.5Operating margin -11.88%, StockStory '3 reasons to sell', 1h/4h forecasts negative.
23CWHAVOID3.3Debt/eq 19, negative margins, PT cuts, and 1wk fc +207% is a data-quality outlier.
24COURAVOID3.1Near_term_bullish 0.0, negative margins, 1h fc_short/mid both negative.
25MVSTAVOID2.6Governance investigation + exec departure, sales -10.44%, penny-stock tape.
26BWINAVOID2.2Bullish_prob 0.2, all four TFs show negative forecasts, already ran +57% — sell-side is now cautious.

Get AI top picks & forecasts on any stock

K3vl4r screens the market daily and ranks the best setups with AI — forecasts, scored fundamentals & technicals, and multi-horizon price targets. Create a free account to explore them all.

Create your free account →

Already a member? Sign in · Join our Discord

⚠️ This AI-generated analysis is for informational purposes only and is not financial advice. Forecasts and scores are model outputs that can be wrong; markets involve substantial risk of loss. Do your own research.